Tarsus Pharmaceuticals, Inc. (TARS): R&D Expense
$64.32M
Year ended 2025-12-31
$87.68M
Trailing 12 months to 2026-06-30
+14.7%
3-year compound annual growth
+27.9%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $64.32M | +20.5% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $53.39M | +6.1% | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $50.31M | +18.0% | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | $42.62M | +2.2% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $41.71M | +121.6% | 2023-03-17, From 2021-01-01 |
| 2020-12-31 | $18.83M | +495.4% | 2022-03-14, From 2020-01-01 |
| 2019-12-31 | $3.16M | n/a | 2021-03-31, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $64.32M | +20.5% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $274.87M | +23.7% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $4.76M | +162.7% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $58.05M | +8.3% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $80.28M | -11.6% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $93.77M | -8.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $27.56M | +11.2% |
| Repligen Corp (RGEN) | 2025-12-31 | $54.18M | +25.4% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $300.27M | +8.7% |
Compare TARS, IMCR, ADMA, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗